BioTech IP Review

• Assignee: Genentech, Inc.
• Patent Number: 12,384,844
• Filing Date: May 12, 2022 (priority to May 14, 2021)
• Patent Issued: August 12, 2025
• Inventors: Ainhoa Echeverria Larraza, David Verne Hansen, Yi-Chun Hsiao, Zhonghua Lin, Dhaya Seshasayee, Benny Chih (among others)

---

What It Covers

This patent protects antibodies that act as agonists of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) — i.e., engineered antibodies that specifically bind to and activate the TREM2 receptor on immune cells.

Key technical components:

• TREM2-binding antibodies:
  The antibodies are designed with specific heavy and light chain variable region sequences that bind with high affinity to the TREM2 receptor, especially in a way that preferentially engages the stalk domain and avoids binding soluble TREM2 — a form shed from cells that can reduce efficacy.
• Agonist biological activity:
  These antibodies aren’t just binders — they stimulate TREM2 signaling in microglia or other myeloid cells. TREM2 activation has been linked to improved phagocytosis, enhanced cell survival, and modulation of inflammatory responses.
• Antibody structure and formats:
  The patent details antibody CDR (complementarity determining region) sequences, variable region sequences, and full-length IgG formats that are effective TREM2 agonists.

---

Why It’s Important

1. Neurodegenerative disease potential

TREM2 is a critical regulator of microglial function in the brain, where these immune cells play roles in clearing amyloid plaques and damaged neurons. Activating TREM2 is a leading therapeutic strategy in Alzheimer’s disease (AD) and other neurodegenerative conditions where immune dysfunction contributes to pathology.

2. Strategic expansion beyond oncology

While Genentech is historically strongest in oncology and immunology, a robust TREM2 agonist platform makes it a strong competitor in neurodegeneration therapeutics — a huge emerging market with massive unmet clinical need.

3. Broad therapeutic applications

Beyond AD, TREM2 agonists are being explored for frontotemporal dementia, Parkinson’s disease, ALS (amyotrophic lateral sclerosis), and even certain inflammatory disorders due to the role of myeloid cells in clearing pathogenic signals and regulating immune responses.

4. Strong IP protection window

This patent extends protection on specific therapeutic antibodies into the 2030s, giving Genentech exclusive rights to TREM2 agonist compositions and methods of use — which can underpin future biologic drug filings and commercialization.

---

Summary

U.S. Patent No. 12,384,844 B2, issued to Genentech, Inc. on August 12, 2025, covers engineered agonist antibodies targeting the TREM2 receptor — a promising modality for treating neurodegenerative diseases by enhancing microglial function and modulating immune responses. This patent is strategically important due to its potential applications in high-value therapeutic areas such as Alzheimer’s and other CNS disorders, positioning Genentech as a key player in emerging immune-modulatory neuro-therapeutics.